Galmed Pharmaceuticals
Open
$0.58
Prev. Close
$0.58
High
$0.58
Low
$0.58
Market Snapshot
$3.07M
-0.3
-8.03
5
Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). The firm is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The firm's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The firm's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
emptyResult
Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). The firm is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The firm's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The firm's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
Recently from Cashu
Galmed Pharmaceuticals Advances Aramchol Development for Liver Diseases and Beyond
Galmed Pharmaceuticals Advances Its Focus on Aramchol for Liver Diseases Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company headquartered in Tel Aviv, Israel, recently submits its…
Galmed Pharmaceuticals: Key Developments and Insights in Recent Market Performance
Sure! Please provide the text you'd like me to summarize, and I'll create a 300-word paragraph for you.
Galmed Pharmaceuticals: Key Updates and Future Prospects for Investors.
Sure! Please provide the text you'd like me to summarize, and I'll create a 300-word paragraph for you.
Galmed Pharmaceuticals: Key Updates and Future Prospects for Investors
Please provide the text you'd like me to summarize, and I'll create a 300-word article for you.